Fig. 5.
Effect of rapamycin treatment on the liver tumors of LTsc1KO mice at 12 months of age. Mice were treated with vehicle or rapamycin from 12 to 13 months of age (n=4). Tumors were scored in five 4-µm H&E-stained section, each separated by 0.5 mm, for each liver. (A) Representative H&E- and phospho-S6 stained liver sections from vehicle- and rapamycin-treated LTsc1KO mice showing inhibition of mTORC1 signaling by rapamycin. T, tumor and N, non-tumor. (B) Number of hepatomas and HCCs in the vehicle and rapamycin treated mice. (C,D) Detection and quantification of proliferating hepatocytes by PCNA immunostaining of liver sections from vehicle- and rapamycin-treated LTsc1KO mice. (D) Approximately 200 hepatocytes were counted for each tumor, and data are presented as the mean ± SEM (n=5 hepatomas and 5 HCCs per treatment). *P<0.05 compared to hepatomas in vehicle treated mice, **P<0.01 compared to HCCs in vehicle treated mice. Scale bars, A, 100 µm (100X), C, 50 µm (200X).